Join Our Crew

Scientist/Senior Scientist, Cellular Immunology

Philadelphia, PA

About the Position

Reporting to the head of Cellular Immunology, Preclinical Research, we are seeking an experienced, motivated, and highly skilled Scientist or Senior Scientist to join our Preclinical Research team. Under scientific and technical supervision, the candidate will perform various cell-based assays and other in vitro and ex vivo based assays to contribute to the discovery and development of novel therapeutics at Cabaletta. The position offers growth into additional areas such as translational research and molecular biology, immunology, and cell therapy. The position involves both technical and operational responsibilities.

Responsibilities Include

  • Design, develop, and optimize cell-based antibody interaction assays.
  • Perform and optimize cytotoxicity and flow cytometry assays as needed.
  • Perform and validate ELISpot, ELISA, Luminex, or other assays as needed.
  • Maintain and expand, bank, and manage various cell lines.
  • Manage multiple internal projects for Translational, Analytical, and Manufacturing Sciences, as well as involvement in collaborations with external vendors.
  • Actively contribute to process improvements and the implementation of new technologies.
  • Perform lab associated tasks in accordance with cGLP and Cabaletta Bio lab safety policies and SOPs.
  • Maintain accurate and well-organized records and electronic laboratory notebook.

Required Qualifications

  • M.S. in Biology (or related discipline) with a minimum of 5+ years, or B.S. with a minimum 10+ years, or a Ph.D. with 2+ years of cellular immunology experience will be considered
  • Significant lab experience and expertise in cellular immunology required
  • General lab skills, including aseptic techniques and human tissue handling required
  • Must have prior experience and be highly skilled at mammalian cell culture (aseptic techniques)
  • Experience in primary cell and iPSC derived cell husbandry, cytotoxicity assays, and flow cytometry
  • Must be highly organized and able to work independently
  • Must be able to clearly communicate in writing, must have a desire to be part of a growing organization that uses cutting-edge science
  • A high level of flexibility to support various other activities the ability to learn new techniques outside of existing field of expertise 
  • Strong team orientation and passion for continuous self-development
  • Experience in industry or in a startup industrial setting is preferred

How to Apply

Please email directly to submit an application.

Please include your CV along with the title of the position you are applying for.


Our most important asset is our people and we offer competitive benefits including health and retirement, PTO, and stock option plans.

Equal Opportunity Employer

Cabaletta Bio is an equal opportunity employer. We do not discriminate on the basis of race, color, gender, gender identity, sexual orientation, age, religion, national or ethnic origin, disability, protected veteran status or any other basis protected by applicable law.

About Cabaletta Bio

Cabaletta Bio (NASDAQ: CABA) is focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases. Our proprietary technology utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to precisely bind and destroy only specific autoantibody-expressing B cells while sparing normal antibody-expressing B cells, which are essential for human health. Cabaletta’s Approach for selective B cell Ablation platform, called our CABA™ platform, has applicability across more than two dozen B cell-mediated autoimmune diseases that we have identified, reviewed and prioritized. CAAR T technology is based on the revolutionary Chimeric Antigen Receptor (CAR) T cell technology developed at the University of Pennsylvania that resulted in one of the first commercially-available CAR T cell products for the treatment of B cell malignancies. Cabaletta has an exclusive global licensing agreement and multiple sponsored research agreements with the University of Pennsylvania to develop CAAR T technology to treat B cell-mediated autoimmune diseases.

The Company’s lead product candidate, DSG3-CAART, received IND clearance from the FDA in September 2019, and initial safety data in clinical trials has been reported. DSG3-CAART is designed to be a potential treatment for patients with mucosal pemphigus vulgaris (mPV), which is a rare autoimmune blistering disorder that causes painful blisters and sores on mucous membranes leading to severe and sometimes debilitating and life-altering effects. Cabaletta Bio is also pursuing additional pipeline candidates for other B cell mediated disorders including MuSK Myasthenia Gravis (MG) with an IND planned for 2H 2021, mucocutaneous PV, PLA2R positive membranous nephropathy (PMN), and Factor VIII inhibitors.

Uniquely Differentiated. Rapid. Elegant.

At Cabaletta, we are driven by the shared mission of developing a new type of therapy, where patients’ own cells are used to fight disease. We are building a culture grounded in the knowledge that success in the Cabaletta mission lies in the hands of individuals across every aspect of the company. To nurture this, we make an active commitment to the well-being and continuous growth of each person who joins our team. In this way, we are not only working to improve the lives of patients, but of everyone involved. #CabalettaCrew